Literature DB >> 32557172

Statins in a Distorted Mirror of Media.

Adam J Nelson1,2, Rishi Puri3, Steven E Nissen4.   

Abstract

PURPOSE OF REVIEW: Statins have proven efficacy with a favorable safety profile yet, despite being widely affordable, remain profoundly underutilized. Statins have acquired a bad reputation, which is likely contributing to high rates of nonadherence and discontinuation. The degree to which negative media perceptions contribute to underutilization is unclear. RECENT
FINDINGS: The media has a key role in informing discussion on the public agenda but also on how issues are framed. In this context, the majority of studies evaluating news coverage suggest that the content on statins is predominantly negative and focused on potential harm. Studies utilizing quasi-experimental and interrupted time series design have shown periods of negative news stories on statins in multiple countries are associated with (a) less statin commencement in eligible patients, (b) high rates of discontinuation, and (c) poor long-term adherence. This review highlights the deleterious impact of negative media coverage on statin utilization through misattribution of muscle complaints and the nocebo effect. Academia must work with the media to harmonize the public health messaging; however, individual physicians have a critical role in mitigating a harmful narrative of misinformation and actively discredit malinformation.

Entities:  

Keywords:  Media; Misinformation; Statin intolerance; Statins

Year:  2020        PMID: 32557172     DOI: 10.1007/s11883-020-00853-9

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  7 in total

1.  PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021.

Authors:  Maciej Banach; Paweł Burchardt; Krzysztof Chlebus; Piotr Dobrowolski; Dariusz Dudek; Krzysztof Dyrbuś; Mariusz Gąsior; Piotr Jankowski; Jacek Jóźwiak; Longina Kłosiewicz-Latoszek; Irina Kowalska; Maciej Małecki; Aleksander Prejbisz; Michał Rakowski; Jacek Rysz; Bogdan Solnica; Dariusz Sitkiewicz; Grażyna Sygitowicz; Grażyna Sypniewska; Tomasz Tomasik; Adam Windak; Dorota Zozulińska-Ziółkiewicz; Barbara Cybulska
Journal:  Arch Med Sci       Date:  2021-11-08       Impact factor: 3.318

Review 2.  SAMSON and the Nocebo Effect: Management of Statin Intolerance.

Authors:  Amrita Krishnamurthy; Corey Bradley; Rebecca Ascunce; Samuel M Kim
Journal:  Curr Cardiol Rep       Date:  2022-06-27       Impact factor: 3.955

3.  High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.

Authors:  Adam J Nelson; Kevin Haynes; Sonali Shambhu; Zubin Eapen; Mark J Cziraky; Michael G Nanna; Sara B Calvert; Kerrin Gallagher; Neha J Pagidipati; Christopher B Granger
Journal:  J Am Coll Cardiol       Date:  2022-05-10       Impact factor: 27.203

4.  How to enhance recruitment of individuals at risk of rheumatoid arthritis into trials aimed at prevention: understanding the barriers and facilitators.

Authors:  Laurette van Boheemen; Marieke M Ter Wee; Bart Seppen; Dirkjan van Schaardenburg
Journal:  RMD Open       Date:  2021-03

5.  Association between CVDs and initiation and adherence to statin treatment in patients with newly diagnosed hypercholesterolaemia: a retrospective cohort study.

Authors:  In Sun Ryou; Jooyoung Chang; Joung Sik Son; Ahryoung Ko; Seulggie Choi; Kyuwoong Kim; Sung Min Kim; Sang Min Park
Journal:  BMJ Open       Date:  2021-04-07       Impact factor: 2.692

6.  LDL-cholesterol trajectories and statin treatment in Finnish type 2 diabetes patients: a growth mixture model.

Authors:  Laura Inglin; Piia Lavikainen; Kari Jalkanen; Tiina Laatikainen
Journal:  Sci Rep       Date:  2021-11-19       Impact factor: 4.379

Review 7.  Placebo: a brief updated review.

Authors:  Alfredo Jose Pardo-Cabello; Victoria Manzano-Gamero; Emilio Puche-Cañas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-08-09       Impact factor: 3.195

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.